Eyelid Melanoma and version 1.2

  • Research type

    Research Study

  • Full title

    The Incidence and epidemiology of Eyelid Melanoma in the UK

  • IRAS ID

    252915

  • Contact name

    John Bladen

  • Contact email

    john.bladen1@nhs.net

  • Sponsor organisation

    Kings College Hospital NHS Foundation Trust

  • Duration of Study in the UK

    1 years, 10 months, 1 days

  • Research summary

    The incidence of malignant eyelid melanoma is unknown along with its clinical, visual, histological, genomic and prognostic characteristics. Anecdotal evidence suggests that the eyelid is a high-risk region and more understanding of this visually threatening disease is required. We aim to establish a current incidence rate for eyelid melanoma using an epidemiological (prospective population-based) study using the British Ophthalmological Surveillance Unit (BOSU) monthly reporting card scheme. This is an active surveillance system involving all UK ophthalmologists with clinical autonomy (consultant and associate specialist grade). The study uses only information available from the patient case notes.

    Ophthalmologists will indicate that they have seen a new eyelid melanoma case through the BOSU. The BOSU collects no patient identifying information but will notify the study investigator (Dr John Bladen) of all ophthalmologists who report new cases. The researcher will then contact the reporting ophthalmologist directly and will be sent a questionnaire requesting information to determine the incidence, but also secondary aims of histological subtype, the treatment given, prognosis and the effect on vision.

    Research analysis will be carried out at one site at Kings College Hospital (Princess Royal University Hospital (PRUH)). No procedures mentioned in the Standard Operating Procedures for ethics committees in the United Kingdom will be carried out which require a principal investigator to be appointed at each site. Analysis will be descriptive and all findings reported in an aggregated format and at no point will the patient’s routine standard care be altered or impacted as a result of this study.

  • REC name

    London - London Bridge Research Ethics Committee

  • REC reference

    19/LO/0862

  • Date of REC Opinion

    4 Jun 2019

  • REC opinion

    Favourable Opinion